Asthika Goonewardene
Stock Analyst at Truist Securities
(1.18)
# 3,428
Out of 4,712 analysts
83
Total ratings
32%
Success rate
-13.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Maintains: Buy | $87 → $136 | $79.02 | +72.11% | 5 | Nov 12, 2024 | |
| GILD Gilead Sciences | Maintains: Hold | $83 → $97 | $94.41 | +2.74% | 1 | Nov 8, 2024 | |
| EXEL Exelixis | Maintains: Buy | $33 → $38 | $34.03 | +11.67% | 6 | Oct 30, 2024 | |
| IGMS IGM Biosciences | Downgrades: Hold | $24 → $12 | $6.65 | +80.45% | 7 | Oct 1, 2024 | |
| GMAB Genmab | Maintains: Buy | $53 → $50 | $20.58 | +142.95% | 13 | Sep 9, 2024 | |
| STRO Sutro Biopharma | Maintains: Buy | $18 → $15 | $1.97 | +661.42% | 6 | Aug 16, 2024 | |
| ALLO Allogene Therapeutics | Reiterates: Buy | $17 → $14 | $2.17 | +545.16% | 6 | Aug 9, 2024 | |
| RCUS Arcus Biosciences | Maintains: Buy | $50 → $44 | $15.83 | +177.95% | 1 | Jun 24, 2024 | |
| LEGN Legend Biotech | Initiates: Buy | $88 | $32.78 | +168.46% | 1 | Jun 17, 2024 | |
| MRUS Merus | Maintains: Buy | $69 → $88 | $43.10 | +104.18% | 2 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.63 | +145.40% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $1.70 | +1,017.65% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 → $32 | $14.89 | +114.91% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $26 | $7.60 | +242.11% | 5 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $1.42 | +533.80% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $1.85 | +2,062.16% | 4 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $0.96 | +2,712.50% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $9 | $2.30 | +291.30% | 3 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $21.40 | +460.75% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $2.14 | +2,703.74% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $0.83 | +1,712.03% | 4 | Aug 23, 2022 |
Arcellx
Nov 12, 2024
Maintains: Buy
Price Target: $87 → $136
Current: $79.02
Upside: +72.11%
Gilead Sciences
Nov 8, 2024
Maintains: Hold
Price Target: $83 → $97
Current: $94.41
Upside: +2.74%
Exelixis
Oct 30, 2024
Maintains: Buy
Price Target: $33 → $38
Current: $34.03
Upside: +11.67%
IGM Biosciences
Oct 1, 2024
Downgrades: Hold
Price Target: $24 → $12
Current: $6.65
Upside: +80.45%
Genmab
Sep 9, 2024
Maintains: Buy
Price Target: $53 → $50
Current: $20.58
Upside: +142.95%
Sutro Biopharma
Aug 16, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $1.97
Upside: +661.42%
Allogene Therapeutics
Aug 9, 2024
Reiterates: Buy
Price Target: $17 → $14
Current: $2.17
Upside: +545.16%
Arcus Biosciences
Jun 24, 2024
Maintains: Buy
Price Target: $50 → $44
Current: $15.83
Upside: +177.95%
Legend Biotech
Jun 17, 2024
Initiates: Buy
Price Target: $88
Current: $32.78
Upside: +168.46%
Merus
Jun 4, 2024
Maintains: Buy
Price Target: $69 → $88
Current: $43.10
Upside: +104.18%
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $1.63
Upside: +145.40%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $1.70
Upside: +1,017.65%
May 16, 2024
Reiterates: Buy
Price Target: $34 → $32
Current: $14.89
Upside: +114.91%
Mar 7, 2024
Maintains: Buy
Price Target: $17 → $26
Current: $7.60
Upside: +242.11%
Feb 29, 2024
Upgrades: Buy
Price Target: $9
Current: $1.42
Upside: +533.80%
Sep 6, 2023
Reiterates: Buy
Price Target: $40
Current: $1.85
Upside: +2,062.16%
Sep 6, 2023
Reiterates: Buy
Price Target: $27
Current: $0.96
Upside: +2,712.50%
Aug 17, 2023
Maintains: Buy
Price Target: $6 → $9
Current: $2.30
Upside: +291.30%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $21.40
Upside: +460.75%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $2.14
Upside: +2,703.74%
Aug 23, 2022
Maintains: Buy
Price Target: $19 → $15
Current: $0.83
Upside: +1,712.03%